Rawstron Andy C
Leeds Teaching Hospitals, United Kingdom.
Curr Protoc Cytom. 2006 May;Chapter 6:Unit6.23. doi: 10.1002/0471142956.cy0623s36.
Plasma cell enumeration and immunophenotyping has been shown to be of value in predicting the outcome for patients with myeloma. Detection of abnormal plasma cells at a leukocyte level >0.01% at the end of therapy predicts early relapse. Although clonally related populations at varying stages of differentiation are reported to be present in myeloma, only the CD138+ fraction has been shown to directly correlate with the outcome. In addition, the plasma cell immunophenotype in monoclonal gammopathy of undetermined significance (MGUS) is reported to correlate with the risk of progression to myeloma. This protocol provides a four-color flow cytometry method for enumeration and classification of plasma cells in both diagnostic and post-treatment samples. Plasma cells are identified by strong expression of CD38 and CD138. Neoplastic plasma cells are separated from their normal counterparts by aberrant expression of CD19 and other relevant markers in combination with intracellular immunoglobulin light chain restriction.
浆细胞计数和免疫表型分析已被证明在预测骨髓瘤患者的预后方面具有价值。治疗结束时白细胞水平>0.01%时检测到异常浆细胞可预测早期复发。虽然据报道骨髓瘤中存在处于不同分化阶段的克隆相关群体，但只有CD138+部分已被证明与预后直接相关。此外，据报道意义未明的单克隆丙种球蛋白病（MGUS）中的浆细胞免疫表型与进展为骨髓瘤的风险相关。本方案提供了一种四色流式细胞术方法，用于诊断和治疗后样本中浆细胞的计数和分类。通过CD38和CD138的强表达来鉴定浆细胞。肿瘤性浆细胞通过CD19和其他相关标志物的异常表达以及细胞内免疫球蛋白轻链限制与正常对应物分离。
